The European Commission’s (EC) Scientific Committee on Consumer Safety (SCCS) has updated its zinc oxide opinion to include comments received on the subject. Nevertheless the following conclusion remains the same: 'on the basis of available evidence...the use of ZnO nanoparticles with the characteristics as indicated...can be considered not to pose a risk of adverse effects in humans after dermal application'.
Comments were received over a four week period following the initial publication of the opinion. Small alterations were made to the conclusions contained within the initial opinion:
- Text was added to state that ‘data on the purity was not provided in the physico-chemical characterization section, and was also not provided in the various study reports cited although in one report a content of 100% was indicated’
- A section where the SCCS points out a re-evaluation of toxicity testing may be needed now reads ‘in the case of use of other specific coatings or specific absorption enhancers in the formulation, which can promote the dermal penetration of ZnO particles (nano or non-nano), or indications of dermal absorption after long term use of nano ZnO containing formulations’.
The committee discussed the comments at the 27th meeting of the Nanomaterials in Cosmetic Products Working Group (WG), which took place in November 2012.
Follow this link to read the revised opinion on nanoform zinc oxide. Follow this link to read the NIA’s reporting on the initial opinion, and this link to read the NIA’s coverage of the meeting at which the comments were considered.